Dec. 8, 2021– In the nearly three years since the Health Resources & Services Administration (HRSA) launched its 340B drug pricing program ceiling price website, 41 drug companies have acknowledged that they overcharged 340B hospitals, health centers, and clinics and would refund those affected. This contrasts with only seven such reports in the two years prior to the … [Read more...]